Antidepressant Safety Fallout Not Impacting Lexapro, Celexa, Forest Says
Executive Summary
Publicity surrounding the safety of antidepressants in adult and pediatric patients is not having an impact on Forest's sales of Lexapro and Celexa, President Kenneth Goodman said during a July 20 investor call
You may also be interested in...
Antidepressant Investigations Continue; GAO Studying FDA Process
The Government Accountability Office is studying how FDA resolves internal disputes about drug safety issues
Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out
Eight out of 10 antidepressant manufacturers asked by FDA to include a class warning in labeling on suicide risks have complied with the agency's request
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer